Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among […]
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) has received an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among […]
StockNews.com downgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) from a hold rating to a sell rating in a research note published on Monday morning. A number of other analysts have also recently issued reports on the company. HC Wainwright lowered their target price on Syros Pharmaceuticals from $100.00 to $60.00 and set a […]
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) saw a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 3,510,000 shares, a decline of 14.8% from the May 15th total of 4,120,000 shares. Currently, 8.0% of the shares of the stock are sold short. Based on […]
Equities analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Rating) will report $4.94 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with estimates ranging from $3.20 million to $6.01 million. Syros Pharmaceuticals reported sales of $5.16 million in the same quarter […]